Study identifier:D1532C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase II, open, randomised study to assess the efficacy and safety of AZD6244 versus pemetrexed (Alimta®) in patients with non-small cell lung cancer, who have failed one or two prior chemotherapy regimen
Non-small Cell Lung Cancer
Phase 2
No
AZD6244, Pemetrexed
All
88
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Aug 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to assess the effect and safety of AZD6244(ARRY-142886)versus pemetrexed in the second or third line treatment of advanced Non-Small Cell Lung Cancer. Following baseline assessments, a minimum of 64 patients in approximately 5-6 centers from the US will be treated with either AZD6244 or pemetrexed. Treatment will be continued for as long as patients receive clinical benefit.
Location
Location
Ann Arbor, MI, United States
Location
New York, NY, United States
Location
Nashville, TN, United States
Location
Los Angeles, CA, United States
Location
sofia, Bulgaria
Location
Plovdiv, Bulgaria
Location
Varna, Bulgaria
Location
Cluj-Napoca, Romania
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Pemetrexed | Drug: Pemetrexed oral Other Name: Alimta® |
Experimental: 2 AZD6244 | Drug: AZD6244 oral vial Other Name: ARRY-142886 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.